-
1 month ago | 
europe.ophthalmologytimes.com | Hattie Jean Hayes
Francesco Bandello, MD, FEBO, discusses the Diabetic Eye Conditions Coalition and a five-point call to action
-
2 months ago | 
hattiejeanhayes.substack.com | Hattie Jean Hayes
Good morning! Or, whatever time it is when you read this. I forgot to tell you guys! January 24th was the 6-year anniversary of the time I was on the bus, listening to Björk, and then the bus almost hit a lady (she’s fine) (the lady) (and Björk). I was living in Queens at the time, and the bus stop across the street from my apartment was the origin/terminal point for the Q18 route.
-
Oct 19, 2024 | 
europe.ophthalmologytimes.com | David Hutton |Hattie Jean Hayes
A novel oral therapeutic showed promising results in a Phase 2 study involving 13 subjects
-
Sep 20, 2024 | 
europe.ophthalmologytimes.com | Hattie Jean Hayes
We spoke with Andrea Govetto, MD, PhD, winner of the inaugural Ramin Tadayoni Award at EURETINA
-
May 5, 2024 | 
optometrytimes.com | Hattie Jean Hayes |Martin Harp |Sydney M Crago |Modern Retina
Myopia management remains on the forefront of prevalent eye care needs, particularly in children. David A. Berntsen, OD, PhD, FAAO, discusses the results of the BLINK2 study, which focuses on the axial length growth after discontinuing soft multifocal contact lens wear in bifocal lenses in children with myopia.
-
Mar 4, 2024 | 
optometrytimes.com | Sydney M Crago |Modern Retina |Hattie Jean Hayes |Emily Kaiser Maharjan
The US Food and Drug Administration (FDA) has approved clobetasol propionate ophthalmic suspension 0.05% (APP13007) by Taiwan-based Formosa Pharmaceuticals and AimMax Therapeutics.
-
Jan 8, 2024 | 
europe.ophthalmologytimes.com | Hattie Jean Hayes
On Monday, the European Commission granted marketing authorisation for aflibercept (Eylea) 8mg. Bayer AG, based in Berlin, Germany, announced the approval in a press release.1 In November 2023, the European Medicines Agency recommended approval of aflibercept 8 mg to the European Commission.2 The approval follows prior approval of aflibercept 2 mg in the European Union.
-
Dec 27, 2023 | 
ophthalmologytimes.com | Hattie Jean Hayes
As 2023 nears its end, the reporters and editors from the Eye Care Network would like to thank you–our readers–for engaging with our print magazine, eNewsletters and video interviews. Throughout the year, we have had the privilege of working alongside industry opinion leaders to showcase what’s new and what’s upcoming in the ophthalmology space. If 2023 has shown us anything, it is how much we have to look forward to in 2024 and beyond.
-
Dec 26, 2023 | 
modernretina.com | Hattie Jean Hayes
As 2023 nears its end, the reporters and editors from the Eye Care Network would like to thank you–our readers–for engaging with our print magazine, eNewsletters and video interviews. Throughout the year, we have had the privilege of working alongside industry opinion leaders to showcase what’s new and what’s upcoming in the ophthalmology space. If 2023 has shown us anything, it is how much we have to look forward to in 2024 and beyond.
-
Dec 18, 2023 | 
europe.ophthalmologytimes.com | Hattie Jean Hayes
Throughout 2023, each ophthalmology meeting featured updates on the latest glaucoma devices. We spoke to Sheng Lim, MD, professor of glaucoma studies at St. Thomas' Hospital and King's College London. He commented on the wide array of glaucoma devices that are going to make waves in the next year. “There are many new technologies that are just being introduced, or we’re waiting for a pivotal study to prove its efficacy,” he said.
